Data Sharing Statement

Data
Data available: Yes
Data types: Other (please specify)
Additional Information: Data related to clarification or validation results in the present publication will be made available upon reasonable request to the corresponding author (john.mcmurray@glasgow.ac.uk). The DAPA-HF Publications Committee has prespecified numerous additional analyses which will lead to scientific presentations and publications. Trial data will be made available by the sponsor, AstraZeneca, in accordance with their data sharing policy described at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
How to access data:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
When available: From 12 months after completion of the last regulatory submission.

Supporting Documents
Document types: A redacted Clinical Report package will be made available soon after conclusion of the trial and will include the Clinical Overview, Clinical Summary, CSR, Protocol, sample CRF and Study Statistical Analysis Plan and will be edited to remove proprietary information, or information that could be used to identify a patient.

Additional Information
Who can access the data: Researchers registered with the AstraZeneca Data Request Portal.
Types of analyses: Requests approved by an independent Scientific Review Board as described at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Mechanisms of data availability: The full process for obtaining data is described at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Any additional restrictions: Some e.g. certain countries prohibit secondary use of data. The full policy is described at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure